Dear doctor: We really are not sure what dose of capecitabine you should prescribe for your patient

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1434-1435

  Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE;

CANCER CHEMOTHERAPY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG CLEARANCE; DRUG LABELING; DRUG MANUFACTURE; DRUG SAFETY; EDITORIAL; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0037087584     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.6.1434     Document Type: Editorial

References (15)

1. 5-Fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer
2. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
3. Carboplatin dosing based on measurement of renal function: Experience at the Peter MacCallum Cancer Institute
4. Geriatric renal function: Estimating glomerular filtration in an ambulatory elderly population
5. Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients
6. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation - Modification of diet in renal disease study group
7. Estimation of glomerular filtration rate in cancer patients
8. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
9. A phase I study of oxaliplatin in cancer patients with impaired renal function
10. Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit?
11. Body surface area as a determinant of pharmacokinetics and drug dosing
12. Gazing into a crystal ball: Cancer therapy in the post-genomic era